The respiratory syncytial virus vaccine landscape: lessons from the graveyard and promising candidates

The global burden of disease caused by respiratory syncytial virus (RSV) is increasingly recognised, not only in infants, but also in older adults (aged ≥65 years). Advances in knowledge of the structural biology of the RSV surface fusion glycoprotein have revolutionised RSV vaccine development by p...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:The Lancet infectious diseases Ročník 18; číslo 10; s. e295 - e311
Hlavní autoři: Mazur, Natalie I, Higgins, Deborah, Nunes, Marta C, Melero, José A, Langedijk, Annefleur C, Horsley, Nicole, Buchholz, Ursula J, Openshaw, Peter J, McLellan, Jason S, Englund, Janet A, Mejias, Asuncion, Karron, Ruth A, Simões, Eric AF, Knezevic, Ivana, Ramilo, Octavio, Piedra, Pedro A, Chu, Helen Y, Falsey, Ann R, Nair, Harish, Kragten-Tabatabaie, Leyla, Greenough, Anne, Baraldi, Eugenio, Papadopoulos, Nikolaos G, Vekemans, Johan, Polack, Fernando P, Powell, Mair, Satav, Ashish, Walsh, Edward E, Stein, Renato T, Graham, Barney S, Bont, Louis J
Médium: Journal Article
Jazyk:angličtina
Vydáno: United States Elsevier Ltd 01.10.2018
Elsevier B.V
Elsevier Limited
Témata:
Adults
Antibodies, Monoclonal - immunology
Antibodies, Viral - immunology
Antigens
Candidates
Children
Clinical trials
COVID-19 vaccines
Disease prevention
Global Health
Glycoproteins
Humans
Immunoglobulins
Immunology
Infants
Infections
Infectious diseases
Medical research
Monoclonal antibodies
Mutation
Nanoparticles
Older people
Proteins
Respiratory syncytial virus
Respiratory Syncytial Virus Infections - prevention & control
Respiratory Syncytial Virus Vaccines - immunology
Vaccine development
Vaccines
Viruses
World Health Organization
United States > US
ISSN:1473-3099, 1474-4457, 1474-4457
On-line přístup:Získat plný text
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
Popis
Shrnutí:The global burden of disease caused by respiratory syncytial virus (RSV) is increasingly recognised, not only in infants, but also in older adults (aged ≥65 years). Advances in knowledge of the structural biology of the RSV surface fusion glycoprotein have revolutionised RSV vaccine development by providing a new target for preventive interventions. The RSV vaccine landscape has rapidly expanded to include 19 vaccine candidates and monoclonal antibodies (mAbs) in clinical trials, reflecting the urgency of reducing this global health problem and hence the prioritisation of RSV vaccine development. The candidates include mAbs and vaccines using four approaches: (1) particle-based, (2) live-attenuated or chimeric, (3) subunit, (4) vector-based. Late-phase RSV vaccine trial failures highlight gaps in knowledge regarding immunological protection and provide lessons for future development. In this Review, we highlight promising new approaches for RSV vaccine design and provide a comprehensive overview of RSV vaccine candidates and mAbs in clinical development to prevent one of the most common and severe infectious diseases in young children and older adults worldwide.
Bibliografie:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
ObjectType-Review-3
content type line 23
ISSN:1473-3099
1474-4457
1474-4457
DOI:10.1016/S1473-3099(18)30292-5